SVE Stock Overview
A pharmaceutical company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Synthaverse S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł4.40 |
| 52 Week High | zł5.93 |
| 52 Week Low | zł3.55 |
| Beta | 1.16 |
| 11 Month Change | 1.97% |
| 3 Month Change | -4.86% |
| 1 Year Change | -9.24% |
| 33 Year Change | -39.61% |
| 5 Year Change | 349.90% |
| Change since IPO | -8.33% |
Recent News & Updates
Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is Lacking
Apr 20
Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its Problems
Apr 18Recent updates
Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is Lacking
Apr 20Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its Problems
Apr 18BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite Sensibly
Oct 14More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%
Nov 29We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) Earnings
Nov 16Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?
May 02Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?
Mar 08What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?
Jan 29
Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Jan 03BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of Debt
Dec 07Shareholder Returns
| SVE | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | -1.6% | -4.5% | -3.3% |
| 1Y | -9.2% | -16.2% | 1.1% |
Return vs Industry: SVE exceeded the Polish Biotechs industry which returned -16.2% over the past year.
Return vs Market: SVE underperformed the Polish Market which returned 1.1% over the past year.
Price Volatility
| SVE volatility | |
|---|---|
| SVE Average Weekly Movement | 3.2% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in PL Market | 8.6% |
| 10% least volatile stocks in PL Market | 3.0% |
Stable Share Price: SVE has not had significant price volatility in the past 3 months compared to the Polish market.
Volatility Over Time: SVE's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1944 | 239 | Mieczyslaw Starkowicz | www.synthaverse.pl |
Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company’s prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50 and BCG 100 products for treating superficial (non-muscle invasive) bladder tumor; GAMMA anty HBs 200 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products used in prevention of hemolytic disease of the foetus and newborn; BioTrombina 400, a medication for topical control of severe bleeding; and Anti-Tuberculosis Vaccine BCG 10, a medication used in tuberculosis prevention. It also offers medical products comprising Ram blood for laboratory use; stonebrink medium for biovine Mycobacterium tuberculosis diagnostics; Löwenstein-Jensen medium with medicines for testing medicine susceptibility of Mycobacterium tuberculosis; Löwenstein-Jensen medium containing glycerolfor is used for identification of Mycobacterium tuberculosis; Ox Thrombin for in-vitro diagnostics and Lyophilisate; and rabbit plasma.
Synthaverse S.A. Fundamentals Summary
| SVE fundamental statistics | |
|---|---|
| Market cap | zł309.20m |
| Earnings (TTM) | zł2.47m |
| Revenue (TTM) | zł57.35m |
125.0x
P/E Ratio5.4x
P/S RatioIs SVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SVE income statement (TTM) | |
|---|---|
| Revenue | zł57.35m |
| Cost of Revenue | zł22.61m |
| Gross Profit | zł34.74m |
| Other Expenses | zł32.27m |
| Earnings | zł2.47m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 20, 2024
| Earnings per share (EPS) | 0.035 |
| Gross Margin | 60.57% |
| Net Profit Margin | 4.31% |
| Debt/Equity Ratio | 69.4% |
How did SVE perform over the long term?
See historical performance and comparison